Stella Pharma Corporation (4888.T)
JPY 328.0
(0.31%)
JPY 328.0
(0.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -763.74 Million JPY | 1.94% |
| 2022 | -778.82 Million JPY | -1.45% |
| 2021 | -767.71 Million JPY | -16.45% |
| 2020 | -659.24 Million JPY | 31.47% |
| 2019 | -962 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -161.76 Million JPY | 45.01% |
| 2023 Q2 | -140.15 Million JPY | 15.41% |
| 2023 FY | -763.74 Million JPY | 1.94% |
| 2023 Q4 | -294.18 Million JPY | -79.71% |
| 2023 Q3 | -163.7 Million JPY | -16.8% |
| 2023 Q1 | -165.69 Million JPY | 43.95% |
| 2022 Q3 | -139.07 Million JPY | 5.62% |
| 2022 FY | -778.82 Million JPY | -1.45% |
| 2022 Q4 | -295.6 Million JPY | -112.55% |
| 2022 Q2 | -147.35 Million JPY | 0.0% |
| 2021 FY | -767.71 Million JPY | -16.45% |
| 2020 FY | -659.24 Million JPY | 31.47% |
| 2019 FY | -962 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 298.893% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -44.948% |
| GNI Group Ltd. | 8.09 Billion JPY | 109.436% |
| Linical Co., Ltd. | 338.26 Million JPY | 325.784% |
| Trans Genic Inc. | 4.08 Million JPY | 18796.426% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 46.886% |
| Soiken Holdings Inc. | -662.2 Million JPY | -15.335% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 652.82% |
| AnGes, Inc. | -7.43 Billion JPY | 89.731% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 40.709% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 89.382% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 509.091% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 2.084% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 33.754% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 36.828% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 5.99% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -135.971% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 37.399% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 46.293% |
| PeptiDream Inc. | 3.03 Billion JPY | 125.158% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 60.601% |
| Ribomic Inc. | -1.02 Billion JPY | 25.432% |
| SanBio Company Limited | -2.64 Billion JPY | 71.114% |
| Healios K.K. | -3.82 Billion JPY | 80.022% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 34.615% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 48.728% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 46.568% |
| StemRIM | -2.02 Billion JPY | 62.228% |
| CellSource Co., Ltd. | 923.14 Million JPY | 182.734% |
| FunPep Company Limited | -933.41 Million JPY | 18.177% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 10.584% |
| TMS Co., Ltd. | -960.04 Million JPY | 20.446% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 32.412% |
| Cuorips Inc. | -632.18 Million JPY | -20.811% |
| K Pharma,Inc. | 260.33 Million JPY | 393.377% |
| Takara Bio Inc. | 1.48 Billion JPY | 151.605% |
| ReproCELL Incorporated | -31.41 Million JPY | -2331.16% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 2995.401% |
| StemCell Institute Inc. | 310.98 Million JPY | 345.593% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 633.46% |
| CellSeed Inc. | -846.53 Million JPY | 9.779% |